Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer ...Middle East

SAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study...

Hence then, the article about mirati presents two year follow up data from krystal 1 study demonstrating durable response and long term overall survival at 2023 world conference on lung cancer was published today ( Sunday 10/09/2023 - 05:44 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer )

Also on site :

• Julie Greenwald and Max Lousada Launch 26.2, a New Label, in Partnership With Sony Music
• Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
• MP brandishes Israeli flag with swastika in Polish parliament (VIDEO)